Startseite>>Signaling Pathways>> Membrane Transporter/Ion Channel>> P2X purinergic receptor>>(E/Z)-Sivopixant

(E/Z)-Sivopixant (Synonyms: (E/Z)-S-600918)

Katalog-Nr.GC62560

(E/Z)-Sivopixant ((E/Z)-S-600918) ist ein potenter P2X3-Rezeptorantagonist mit einem IC50 von 4 nM.

Products are for research use only. Not for human use. We do not sell to patients.

(E/Z)-Sivopixant Chemische Struktur

Cas No.: 1640808-39-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
453,00 $
Auf Lager
5 mg
405,00 $
Auf Lager
10 mg
720,00 $
Auf Lager
25 mg
1.485,00 $
Auf Lager
50 mg
2.295,00 $
Auf Lager
100 mg
3.420,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(E/Z)-Sivopixant (Compound I-127) is a potent P2X3 receptor antagonist with an IC50 of 4 nM. (E/Z)-Sivopixant can be used for respiratory diseases research[1].

ATP receptors are roughly classified into an ion channel type P2X family and a G protein coupled type P2Y family. Seven types of subtypes have been reported in the P2X receptor family, and function as non-selective cation channels by forming homotrimers or heterotrimers with other P2X subtypes. Furthermore, P2X3 that the receptor is expressed in neuroepithelial bodies (NEB) of the lungs, and ATP-induced cough, etc., P2X3 receptors It has been suggested that it is involved in information transmission in the respiratory organs[1].

[1]. Kai, Hiroyuki, et al. Amino-triazine derivatives and pharmaceutical composition containing said derivatives. WO2014200078A1.

Bewertungen

Review for (E/Z)-Sivopixant

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (E/Z)-Sivopixant

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.